X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (725) 725
index medicus (529) 529
oncology (519) 519
hematology (489) 489
female (440) 440
male (431) 431
middle aged (420) 420
rituximab (405) 405
indolent lymphoma (378) 378
aged (372) 372
adult (335) 335
non-hodgkins-lymphoma (324) 324
indolent (309) 309
follicular lymphoma (283) 283
antineoplastic combined chemotherapy protocols - therapeutic use (237) 237
treatment outcome (225) 225
chemotherapy (222) 222
lymphomas (221) 221
aged, 80 and over (181) 181
chronic lymphocytic-leukemia (169) 169
therapy (153) 153
lymphoma (150) 150
cancer (145) 145
lymphoma, follicular - drug therapy (141) 141
prognosis (133) 133
trial (129) 129
disease-free survival (128) 128
1st-line treatment (127) 127
b-cell lymphoma (126) 126
antineoplastic agents - therapeutic use (125) 125
bendamustine (124) 124
lymphoma, non-hodgkin - drug therapy (120) 120
plus rituximab (120) 120
care and treatment (115) 115
mantle cell lymphoma (114) 114
anti-cd20 monoclonal-antibody (111) 111
survival (108) 108
antibodies, monoclonal, murine-derived (106) 106
fludarabine (105) 105
low-grade (101) 101
phase-ii (99) 99
antibodies, monoclonal - therapeutic use (94) 94
recurrence (94) 94
retrospective studies (94) 94
antineoplastic combined chemotherapy protocols - adverse effects (93) 93
survival analysis (90) 90
cyclophosphamide (89) 89
multicenter (86) 86
lymphoma, follicular - pathology (85) 85
antineoplastic combined chemotherapy protocols - administration & dosage (83) 83
medicine & public health (83) 83
non-hodgkin-lymphoma (83) 83
neoplasm staging (82) 82
non-hodgkin's lymphomas (81) 81
transplantation (81) 81
open-label (78) 78
lymphoma, mantle-cell - drug therapy (76) 76
high-dose therapy (75) 75
follow-up studies (73) 73
remission induction (73) 73
vidarabine - analogs & derivatives (73) 73
bendamustine hydrochloride (71) 71
hemic and lymphatic diseases (71) 71
combined modality therapy (70) 70
cyclophosphamide - administration & dosage (69) 69
immunotherapy (69) 69
lymphoma, b-cell - drug therapy (69) 69
survival rate (68) 68
analysis (67) 67
indolent b-cell (67) 67
lymphoma, follicular - mortality (67) 67
lymphoma, follicular - therapy (67) 67
term-follow-up (66) 66
low-grade lymphoma (65) 65
hematology, oncology and palliative medicine (64) 64
leukemia (64) 64
non-hodgkin lymphoma (64) 64
antineoplastic agents (63) 63
phase-ii trial (63) 63
antimitotic agents (61) 61
antibodies, monoclonal, murine-derived - administration & dosage (60) 60
pathology (60) 60
stem-cell transplantation (60) 60
leukemia, lymphocytic, chronic, b-cell - drug therapy (58) 58
progression-free survival (58) 58
combination (56) 56
immune system diseases (55) 55
indolent lymphomas (55) 55
research (55) 55
bone-marrow-transplantation (53) 53
classification (53) 53
transplantation, autologous (53) 53
antibodies, monoclonal - administration & dosage (52) 52
antineoplastic agents - administration & dosage (52) 52
antineoplastic agents - adverse effects (52) 52
patients (52) 52
vidarabine - administration & dosage (52) 52
lymphoma, non-hodgkin - pathology (51) 51
rituximab - administration & dosage (51) 51
disease progression (50) 50
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1051) 1051
German (16) 16
French (11) 11
Spanish (4) 4
Polish (3) 3
Portuguese (2) 2
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 10/2008, Volume 112, Issue 7, pp. 2687 - 2693
Journal Article
Blood Reviews, ISSN 0268-960X, 11/2017, Volume 31, Issue 6, pp. 426 - 435
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
British Journal of Haematology, ISSN 0007-1048, 06/2014, Volume 165, Issue 6, pp. 768 - 776
Journal Article
Annals of Hematology, ISSN 0939-5555, 07/2012, Volume 91, Issue 7, pp. 1013 - 1022
Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole group. The aim of this study was to collect all the Italian... 
Rituximab | Bendamustine | Antineoplastic agents | Relapsed lymphoma | SOLID TUMORS | EFFICACY | MANTLE CELL | PHASE-II | TOXICITY | REFRACTORY INDOLENT | THERAPY | CELL LYMPHOMA | CHRONIC LYMPHOCYTIC-LEUKEMIA | MALIGNANCIES | HEMATOLOGY | Recurrence | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Medical Oncology - organization & administration | Multicenter Studies as Topic | Societies, Medical | Treatment Failure | Aged, 80 and over | Adult | Female | Retrospective Studies | Chemotherapy, Adjuvant | Lymphoma, Non-Hodgkin - drug therapy | Lymphoma, Non-Hodgkin - epidemiology | Nitrogen Mustard Compounds - adverse effects | Foundations | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Italy - epidemiology | Aged | Lymphoma, Non-Hodgkin - mortality | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Non-Hodgkin - diagnosis | Medical research | Care and treatment | Antibodies | Transplantation | Non-Hodgkin's lymphomas | T cells | Viral antibodies | Antimitotic agents | Analysis | Medicine, Experimental | Bone marrow | Lymphomas | Tumors | Cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, Issue 17, pp. 216 - 225
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2010, Volume 151, Issue 4, pp. 346 - 353
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 2007, Volume 48, Issue 7, pp. 1299 - 1306
Journal Article